A Phase 2 interventional study of OPC-41061 and OPC-41061 in Chronic Renal Failure, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 4 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-10-22.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Kidney Failure, Chronic with a site in Japan — 1 open to participants now, 3 under way, 2 of them phase 3. Kidney Failure, Chronic · Japan.
Among the 30 studies in Kidney Failure, Chronic with a site in Japan, this one is the 13th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2014, is one of 7 in phase 2, and was the 25th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →1 of the 30 studies in Kidney Failure, Chronic with a site in Japan is open now. Recruiting first, the newest first:
CSL Behring · Sites in Japan, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 8 · Phase 4 8
First in 2000; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 127 across the 24 interventional studies, 600 across the 5 observational. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Otsuka Holdings Co., Ltd. has 3 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies in Kidney Failure, Chronic with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Kidney Failure, Chronic with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to investigate the efficacy and safety of OPC-41061 by 24-week oral administration of OPC-41061 at 15-mg or 30-mg or placebo in patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration and who have daily urine volume of at least 500 mL/day.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 24 week.
Drug: OPC-41061
Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 1 week and then OPC-41061 30 mg/day for 23 weeks
Drug: OPC-41061
Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. Placebo will be administered for 24 week.
Drug: Placebo
Change From Baseline in Daily Urine Volume
Change in daily urine volume from baseline to the end of the treatment was calculated using descriptive statistics.
Time frame: Baseline,End of the treatment
Change in Total Volume of Fluid Removed by Dialysis Per Week
Change in total volume of fluid removed by dialysis per week from baseline to the end of the treatment was calculated using descriptive statistics.
Time frame: Baseline,End of the treatment
| Milestone | OPC-41061 15mg/Day | OPC-41061 30mg/Day | Placebo |
|---|---|---|---|
| Started | 40 | 40 | 44 |
| Completed | 34 | 36 | 29 |
| Not completed | 6 | 4 | 15 |
| Withdrew: Adverse event | 3 | 0 | 2 |
| Withdrew: Physician decision | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 |
| Withdrew: Met withdrawal criteria | 2 | 2 | 5 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 3 |
Change in daily urine volume from baseline to the end of the treatment was calculated using descriptive statistics.
| mL | OPC-41061 15mg/Day | OPC-41061 30mg/Day | Placebo |
|---|---|---|---|
| Change From Baseline in Daily Urine Volume | 169.2 ± 422.2 | 111.8 ± 557.7 | -259.9 ± 463.8 |
Change in total volume of fluid removed by dialysis per week from baseline to the end of the treatment was calculated using descriptive statistics.
| mL | OPC-41061 15mg/Day | OPC-41061 30mg/Day | Placebo |
|---|---|---|---|
| Change in Total Volume of Fluid Removed by Dialysis Per Week | 485.9 ± 1979.3 | 375.4 ± 1721.8 | 1099.5 ± 2160.5 |
Collected over Treatment period. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OPC-41061 15mg/Day | 0/39 (0%) | 6/39 (15.4%) | 34/39 (87.2%) |
| OPC-41061 30mg/Day | 0/39 (0%) | 7/39 (17.9%) | 38/39 (97.4%) |
| Placebo | 0/44 (0%) | 10/44 (22.7%) | 34/44 (77.3%) |
| Event | OPC-41061 15mg/Day | OPC-41061 30mg/Day | Placebo |
|---|---|---|---|
| Shunt stenosisInjury, poisoning and procedural complications | 0/39 | 1/39 | 2/44 |
| Acute myocardial infarctionCardiac disorders | 1/39 | 0/39 | 0/44 |
| Angina pectorisCardiac disorders | 1/39 | 0/39 | 0/44 |
| Cardiac failureCardiac disorders | 1/39 | 0/39 | 0/44 |
| Cardiac failure congestiveCardiac disorders | 0/39 | 1/39 | 0/44 |
| Shunt occlusionInjury, poisoning and procedural complications | 0/39 | 1/39 | 0/44 |
| ContusionInjury, poisoning and procedural complications | 0/39 | 1/39 | 0/44 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/39 | 1/39 | 0/44 |
| Macular holeEye disorders | 0/39 | 1/39 | 0/44 |
| Decreased activityGeneral disorders | 1/39 | 0/39 | 0/44 |
| Event | OPC-41061 15mg/Day | OPC-41061 30mg/Day | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 9/39 | 14/39 | 10/44 |
| ContusionInjury, poisoning and procedural complications | 1/39 | 7/39 | 3/44 |
| DiarrhoeaGastrointestinal disorders | 1/39 | 5/39 | 4/44 |
| VomitingGastrointestinal disorders | 2/39 | 4/39 | 1/44 |
| ThirstGeneral disorders | 4/39 | 3/39 | 1/44 |
| Shunt stenosisInjury, poisoning and procedural complications | 0/39 | 2/39 | 4/44 |
| Blood potassium increasedInvestigations | 2/39 | 0/39 | 4/44 |
| Blood pressure decreasedInvestigations | 3/39 | 1/39 | 2/44 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 3/39 | 0/39 | 1/44 |
| WoundInjury, poisoning and procedural complications | 2/39 | 0/39 | 3/44 |
| Age, Categorical(Participants) | OPC-41061 15mg/Day | OPC-41061 30mg/Day | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 17 | 26 | 22 | 65 |
| >=65 years | 23 | 14 | 22 | 59 |
| Age, Continuous(years) | OPC-41061 15mg/Day | OPC-41061 30mg/Day | Placebo | Total |
|---|---|---|---|---|
| Mean | 64.2 ± 11.0 | 60.5 ± 12.6 | 64.4 ± 8.7 | 63.0 ± 10.8 |
| Sex: Female, Male(Participants) | OPC-41061 15mg/Day | OPC-41061 30mg/Day | Placebo | Total |
|---|---|---|---|---|
| Female | 5 | 11 | 40 | 56 |
| Male | 35 | 29 | 4 | 68 |
| Region of Enrollment(participants) | OPC-41061 15mg/Day | OPC-41061 30mg/Day | Placebo | Total |
|---|---|---|---|---|
| Japan | 40 | 40 | 44 | 122 |
The record gives a start of Dec 2014, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Co., Ltd. →